"Darunavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.
| Descriptor ID |
D000069454
|
| MeSH Number(s) |
D02.065.884.438 D02.241.081.251.222 D02.886.590.700.400 D03.383.312.303
|
| Concept/Terms |
TMC 114- TMC 114
- 114, TMC
- TMC114
- TMC-114
|
Below are MeSH descriptors whose meaning is more general than "Darunavir".
Below are MeSH descriptors whose meaning is more specific than "Darunavir".
This graph shows the total number of publications written about "Darunavir" by people in this website by year, and whether "Darunavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 11 | 4 | 15 |
| 2018 | 16 | 9 | 25 |
| 2019 | 3 | 2 | 5 |
| 2020 | 9 | 12 | 21 |
| 2021 | 1 | 5 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Darunavir" by people in Profiles.
-
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021 Oct; 54(5):767-775.
-
Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathy patients. J Med Virol. 2021 Sep; 93(9):5432-5437.
-
Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora. Pharmazie. 2021 05 01; 76(5):195-201.
-
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital. BMC Infect Dis. 2021 Apr 26; 21(1):382.
-
Authors' Reply to Cattaneo et al.: "Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6". Clin Pharmacokinet. 2021 06; 60(6):833-834.
-
Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". Clin Pharmacokinet. 2021 06; 60(6):829-831.
-
Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia. AIDS Res Hum Retroviruses. 2021 04; 37(4):283-291.
-
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19? Eur Rev Med Pharmacol Sci. 2021 Mar; 25(5):2435-2448.
-
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection. J Antimicrob Chemother. 2021 01 19; 76(2):482-486.
-
Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19. Comb Chem High Throughput Screen. 2021; 24(5):716-728.